Skip to main content

Monte Rosa Therapeutics, Inc. (GLUE)

Sector
Biotechnology
Last price
$9.07
As of

Kresmion compiles this page from GLUE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Monte Rosa Therapeutics, Inc. (GLUE): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.

As of . Source: SEC EDGAR filings for GLUE. Method and limitations.

COMPANY DOSSIER

See the full GLUE dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for GLUE on one page. Preview it with sample data, then open it live with a free account.

Preview the GLUE dossier

Active events for GLUE

FREE, NO ACCOUNT

Every event on GLUE, as it fires

You are seeing 5 of 11 events recorded on GLUE since 2026-05-29.

The five above landed across 2 days. The other 6 were recorded on 2 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, GLUE

More data on GLUE

GLUE against its peers

GLUE's operating margin of -43.8% ranks in the 46th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricGLUEPeer medianPercentilen
Revenue FY124M USD107M USD5411
Operating margin-43.8%-10.1%4611
Net margin-31.2%-15.1%4611
Return on equity-16.6%-41.4%6816
1 year-35.2%17.2%2116

Peers (18): IRWD, ARDX, ORIC, LXRX, PRME, SNDX, SLDB, AURA, RIGL, JANX, MGTX, SGMT, CRVS, TBPH, XOMA.D, PHAR, NVCT, ACHV. Left out: OBX (no annual filing), LTGO (no annual filing), BBTX (no annual filing), IVA (period gap), AKTS (no annual filing), ATTO (no annual filing), CTY (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GLUE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in GLUE on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on GLUE in the last 180 days.

Upstream: SEC EDGAR filings for GLUE

Kresmion, "Monte Rosa Therapeutics, Inc. (GLUE) institutional holdings and SEC filings", data as of 2026-11-11, https://kresmion.com/research/GLUE. Upstream data: SEC EDGAR filings for GLUE.

Link to this data (HTML):

<a href="https://kresmion.com/research/GLUE">Monte Rosa Therapeutics, Inc. (GLUE) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow GLUE on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to GLUE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the GLUE dossier
Share

The GLUE intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.